RxDoctor Payments Data

Muhammad Zafar, MD

Internal Medicine · Flanagan, ILNPI 1811985856

Payments from drug & device makers

$1,954in general payments, 2019–2025

Across 37 payments — averaging $52.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$584
  • Incyte Corporation$300
  • Amgen$198
  • Davol Inc.$176
  • Axonics, Inc.$111
  • Medical Device Business Services, Inc.$101
  • plus $484 from 14 others

What the payments were for

  • Food & beverage$82042%
  • Education$1,13458%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,954 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$990,727
Medicare patients
364
Services billed
31,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VonjoPacritinib Citrate12$316,785
IbrancePalbociclib13$211,004
RevlimidLenalidomide11$201,049
EliquisApixaban303$116,433
JardianceEmpagliflozin189$59,393
OzempicSemaglutide51$58,914
Breo ElliptaFluticasone/Vilanterol76$31,879
XareltoRivaroxaban63$19,858
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog94$16,776
JanuviaSitagliptin Phosphate33$16,650
Incruse ElliptaUmeclidinium Bromide34$15,611
Potassium Chloride354$12,128
Sucralfate165$11,480
Atorvastatin Calcium744$10,788
Gabapentin474$8,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Incruse Ellipta$27$47,490110 claims
MerckJanuvia$46$16,65033 claims
AstraZenecaSymbicort$100$6,93830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Flanagan

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →